Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Centessa Pharmaceuticals PLC Sponsored ADR (CNTA : NSDQ)

• Company Description    Centessa Pharmaceuticals plc is a clinical-stage company employing its innovative asset-centric business model to discover, develop and ultimately deliver impactful medicines to patients. Centessa Pharmaceuticals plc is based in Cambridge, United Kingdom. Number of Employees: 118

• Price / Volume Information    Yesterday's Closing Price: $39.75 Daily Weekly Monthly 20 Day Moving Average: 1,302,048 shares Shares Outstanding: 149.23 (millions) Market Capitalization: $5,931.81 (millions) Beta: 1.13 52 Week High: $40.26 52 Week Low: $10.95 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 0.81% -4.11% 12 Week 48.49% 37.27% Year To Date 58.94% 46.35%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3rd Floor 1 Ashley Road Altrincham - Cheshire,X0 WA14 2DT GBR ph: 1 617 468-5770 fax: - investors@centessa.com http://www.centessa.com

• General Corporate Information    Officers Mario Alberto Accardi - Chief Executive Officer John Crowley - Chief Financial Officer Raphael Deferiere - Chief Accounting Officer Francesco De Rubertis - Director Arjun Goyal - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 152309100 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 03/01/26 Next Expected EPS Date: 08/11/26 Share - Related Items Shares Outstanding: 149.23 Most Recent Split Date: (:1) Beta: 1.13 Market Capitalization: $5,931.81 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.40 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-1.65 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 08/11/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 12.17 Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -160.00% vs. Previous Quarter: -8.33% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 03/31/26 - -60.37 12/31/25 - -50.66 09/30/25 - -49.39 ROA 03/31/26 - -44.17 12/31/25 - -36.65 09/30/25 - -34.64 Current Ratio 03/31/26 - 9.53 12/31/25 - 8.57 09/30/25 - 10.56 Quick Ratio 03/31/26 - 9.53 12/31/25 - 8.57 09/30/25 - 10.57 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - - Pre-Tax Margin 03/31/26 - - 12/31/25 - -1,304.75 09/30/25 - -1,595.38 Book Value 03/31/26 - 3.27 12/31/25 - 3.92 09/30/25 - 2.25 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - 0.23 12/31/25 - 0.21 09/30/25 - 0.36 Debt-to-Capital 03/31/26 - 18.48 12/31/25 - 17.28 09/30/25 - 26.69

Powered by Zacks Investment Research ©